Special Issue Title:

The Role of Surgery in Ovarian Cancer

Deadline for manuscript submissions: 30 December 2021

Print Special Issue Flyer (0)

Special Issue Editor

  • Guest Editor

    Giuseppe Trojano, MD Trojano, MDE-MailWebsite

    Obstetrics and Gynecology Unit, “Madonna delle Grazie” hospital, 75100 Matera, Italy

    Interests: Cancer; Ovarian cancer; Cancer diagnostics; Cancer biomarkers; Cancer prevention; Clinical oncology

  • Guest Editor

    Olga Ostrovsky, PhDE-MailWebsite

    Department of Surgery, Division of Surgical Research, Cooper University Healthcare, Camden, NJ, USA

    Interests: Tissue repair by usage of adipose-derived stem cells; Regulation and prevention of ovarian cancer and metabolic diseases by epigenetic therapy; Role of cannabinoids in post-surgical tissue regeneration and pain control; Regulatory Check points of cell proliferation; Differentiation and regrowth

Special Issue Information

Dear Colleagues,

Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. Primary debulking surgery followed by platinum/taxane-based chemotherapy is the standard of care in advanced EOC. Surgery and platinum‐based chemotherapy are the cornerstones of multimodal treatment in the primary disease setting. The most important prognostic factor for survival is no residual tumour after primary debulking surgery. Two randomised clinical trials comparing Primary debulking surgery and chemotherapy with neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) showed similar survival with a low operative morbidity when NACT and interval debulking surgery were used. The choice between PDS and chemotherapy or NACT and IDS is controversial. Further research is needed on how to select patients for PDS or NACT, including better and validated imaging or laparoscopic scoring systems and algorithms to predict operative morbidity. Systematic pelvic and para-aortic lymphadenectomy in patients with advanced EOC with both intra-abdominal complete resection and clinically negative lymph nodes does not improve overall or progression-free survival. Fertility sparing surgery In young patients with well-differentiated or low-grade, stage IA disease can be considered. Uterus and contralateral ovary can be left in place pending pathology review of the removed tissues and further counseling with the patient. Selection of patients for fertility preservation requires careful consideration of the risks and benefits. The likelihood of cure is high for women with stage IA disease, but residual disease and subsequent recurrence are associated with low likelihood of salvage.

Dr. Giuseppe Trojano and Dr. Olga Ostrovsky

Guest Editors


Ovarian cancer;Primary debulking surgery;Fertility sparing surgery;Platinum/taxane-based chemotherapy

Manuscript Submission Information

Manuscripts should be submitted online by submit system. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Original articles, case reports or comprehensive reviews are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website. Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. European Journal of Gynaecological Oncology is an international peer-reviewed open access journal published by MRE Press. Please visit the Instructions for Authors page before submitting a manuscript.The Article Processing Charge (APC) for publication in this open access journal is $1200. We normally offer a discount greater than 30% to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Share This Special Issue

Plan Papers (0 papers)

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time